Ex Vivo Endotoxin Stimulation of Blood for Predicting Survival in Patients With Sepsis: A Systematic Review

Overview

Journal CHEST Crit Care

Specialty Critical Care

Date 2023 Dec 27

PMID 38148988

Authors

Jonathan Wheelwright

E Scott Halstead

Amy Knehans

Anthony S Bonavia

Affiliations

Soon will be listed here.

Abstract

Background: Sepsis is a syndrome characterized by host immune dysfunction, with the extent of immunoparalysis differing among patients. Lipopolysaccharide (LPS) is used commonly to assess the immune function of critically ill patients with sepsis. However, the reliability of this ex vivo diagnostic test in predicting clinical outcomes remains uncertain.

Research Question: Does LPS-induced tumor necrosis factor (TNF) production from the blood of patients with sepsis predict mortality? Secondary outcomes included ICU and hospital stay durations, nosocomial infection rate, and organ recovery rate.

Study Design And Methods: Human sepsis studies from various databases through April 2023 were evaluated. Inclusion criteria encompassed LPS-stimulated blood assays, English language, and reported clinical outcomes. Bias risk was evaluated using the Newcastle-Ottawa scale (NOS). Relationships between TNF production and mortality were analyzed at sepsis onset and during established sepsis, alongside secondary outcomes.

Results: Of 11,580 studies, 17 studies (14 adult and three pediatric) were selected for analysis. Although 15 studies were evaluated as moderate to high quality using the NOS, it is important to note that some of these studies also had identifiable biases, such as unclear methods of participant recruitment. Nine studies detailed survival outcomes associated with LPS-induced TNF production at sepsis onset, whereas five studies explored TNF production's relationship with mortality during established sepsis. Trends suggested that lower LPS-induced TNF production correlated with higher mortality. However, heterogeneity in methodologies, especially the LPS assay protocol, hindered definitive conclusions. Publication bias was highlighted using funnel plot analysis. Concerning secondary outcomes, diminished TNF production might signify worsening organ dysfunction, although the link between cytokine production and nosocomial infection varied among studies.

Interpretation: For functional immune profiling in sepsis, streamlined research methodologies are essential. This entails organizing cohorts based on microbial sources of sepsis, establishing standardized definitions of immunoparalysis, using consistent types and dosages of immune stimulants, adhering to uniform blood incubation conditions, and adopting consistent clinical outcomes.

Citing Articles

Predicting Organ Dysfunction in Septic and Critically Ill Patients: A Prospective Cohort Study Using Rapid Ex Vivo Immune Profiling.

Samuelsen A, Halstead E, Lehman E, McKeone D, Bonavia A Crit Care Explor. 2024; 6(7):e1106.

PMID: 38916619 PMC: 11208107. DOI: 10.1097/CCE.0000000000001106.

References

van Vught L, Wiewel M, Hoogendijk A, Scicluna B, Belkasim-Bohoudi H, Horn J . Reduced Responsiveness of Blood Leukocytes to Lipopolysaccharide Does not Predict Nosocomial Infections in Critically Ill Patients. Shock. 2015; 44(2):110-4. DOI: 10.1097/SHK.0000000000000391. View

Hotchkiss R, Karl I . The pathophysiology and treatment of sepsis. N Engl J Med. 2003; 348(2):138-50. DOI: 10.1056/NEJMra021333. View

Cavaillon J, Adib-Conquy M . Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 2006; 10(5):233. PMC: 1751079. DOI: 10.1186/cc5055. View

Xaus J, Comalada M, Valledor A, Lloberas J, Lopez-Soriano F, Argiles J . LPS induces apoptosis in macrophages mostly through the autocrine production of TNF-alpha. Blood. 2000; 95(12):3823-31. View

Mancuso G, Midiri A, Beninati C, Piraino G, Valenti A, Nicocia G . Mitogen-activated protein kinases and NF-kappa B are involved in TNF-alpha responses to group B streptococci. J Immunol. 2002; 169(3):1401-9. DOI: 10.4049/jimmunol.169.3.1401. View

Walzer T, Dalod M, Robbins S, Zitvogel L, Vivier E . Natural-killer cells and dendritic cells: "l'union fait la force". Blood. 2005; 106(7):2252-8. DOI: 10.1182/blood-2005-03-1154. View

Vincent J, Moreno R, Takala J, Willatts S, de Mendonca A, Bruining H . The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996; 22(7):707-10. DOI: 10.1007/BF01709751. View

Maddux A, Hiller T, Overdier K, Pyle L, Douglas I . Innate Immune Function and Organ Failure Recovery in Adults With Sepsis. J Intensive Care Med. 2017; 34(6):486-494. DOI: 10.1177/0885066617701903. View

Zhao G, Li D, Zhao Q, Song J, Chen X, Hong G . Incidence, risk factors and impact on outcomes of secondary infection in patients with septic shock: an 8-year retrospective study. Sci Rep. 2016; 6:38361. PMC: 5141415. DOI: 10.1038/srep38361. View

10.

Eguia E, Bunn C, Kulshrestha S, Markossian T, Durazo-Arvizu R, Baker M . Trends, Cost, and Mortality From Sepsis After Trauma in the United States: An Evaluation of the National Inpatient Sample of Hospitalizations, 2012-2016. Crit Care Med. 2020; 48(9):1296-1303. PMC: 7872079. DOI: 10.1097/CCM.0000000000004451. View

11.

Fang W, Douglas I, Chen Y, Lin C, Kao H, Fang Y . Development and validation of immune dysfunction score to predict 28-day mortality of sepsis patients. PLoS One. 2017; 12(10):e0187088. PMC: 5658156. DOI: 10.1371/journal.pone.0187088. View

12.

Buchman T, Simpson S, Sciarretta K, Finne K, Sowers N, Collier M . Sepsis Among Medicare Beneficiaries: 3. The Methods, Models, and Forecasts of Sepsis, 2012-2018. Crit Care Med. 2020; 48(3):302-318. PMC: 7017950. DOI: 10.1097/CCM.0000000000004225. View

13.

Hotchkiss R, Monneret G, Payen D . Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013; 13(3):260-8. PMC: 3798159. DOI: 10.1016/S1473-3099(13)70001-X. View

14.

Leentjens J, Kox M, van der Hoeven J, Netea M, Pickkers P . Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change?. Am J Respir Crit Care Med. 2013; 187(12):1287-93. DOI: 10.1164/rccm.201301-0036CP. View

15.

Sundar K, Sires M . Sepsis induced immunosuppression: Implications for secondary infections and complications. Indian J Crit Care Med. 2013; 17(3):162-9. PMC: 3777370. DOI: 10.4103/0972-5229.117054. View

16.

Hotchkiss R, Monneret G, Payen D . Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013; 13(12):862-74. PMC: 4077177. DOI: 10.1038/nri3552. View

17.

Hall M, Geyer S, Guo C, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J . Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2012; 41(1):224-36. PMC: 3705720. DOI: 10.1097/CCM.0b013e318267633c. View

18.

Albert-Vega C, Tawfik D, Trouillet-Assant S, Vachot L, Mallet F, Textoris J . Immune Functional Assays, From Custom to Standardized Tests for Precision Medicine. Front Immunol. 2018; 9:2367. PMC: 6198655. DOI: 10.3389/fimmu.2018.02367. View

19.

Rhee C, Jones T, Hamad Y, Pande A, Varon J, OBrien C . Prevalence, Underlying Causes, and Preventability of Sepsis-Associated Mortality in US Acute Care Hospitals. JAMA Netw Open. 2019; 2(2):e187571. PMC: 6484603. DOI: 10.1001/jamanetworkopen.2018.7571. View

20.

Ploder M, Pelinka L, Schmuckenschlager C, Wessner B, Jan Ankersmit H, Fuerst W . Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock. 2006; 25(2):129-34. DOI: 10.1097/01.shk.0000191379.62897.1d. View